梯瓦重磅偏头痛新药国内申报上市,百济神州EGFR降解剂1类新药在中国获批临床

医药经济报
22 Jan

瑞玛奈珠单抗是一款人源化单克隆抗体,可选择性结合降钙素基因相关肽(CGRP)配体,并阻断两种 CGRP 亚型(α- 和 β-CGRP)与受体结合,可用于每月至少有 4 天偏头痛的成人患者预防性治疗偏头痛,能显著减少患者的偏头痛发作。瑞玛奈珠单抗是目前唯一一种拥有每季度一次(675mg)和每月一次(225mg)灵活的皮下注射给药选择的 CGRP 单抗类药物。该药已在美国、欧盟、日本等国家和地区获批...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10